Liabilities / Assets
40th percentile
Higher debt load relative to assets than 40% of similar nonprofits.
Siviq Scores
Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.
0.01x
Liabilities / Revenue
35th percentile
Higher debt load relative to revenue than 35% of similar nonprofits.
Net Margin
54th percentile
Higher net margin than 54% of similar nonprofits.
Top Officer Pay
Score unavailable
This filing does not contain officer compensation rows.
Asset Growth
70th percentile
Faster asset growth than 70% of similar nonprofits.
Revenue Growth
53rd percentile
Faster revenue growth than 53% of similar nonprofits.
Balance Sheet
Assets
Up$280,783
Up $34,210 (+14%) from 2022
Net Assets
Up$279,347
Up $32,774 (+13%) from 2022
Liabilities
Up$1,436
Up $1,436 from 2022
Revenue And Expenses
Revenue
Up$540,978
Up $46,102 (+9.3%) from 2022
Expenses
Up$508,204
Up $47,446 (+10%) from 2022
Net Income
Down$32,774
Down $1,344 (-3.9%) from 2022
Historical Trend
Filing Detail Status
This 2023 filing currently has summary financial data only. Detailed schedules, leadership, and program rows are not available for this filing yet.
Jump To
Filing Snapshot
- Filing Period
- Jan 1, 2023 to Dec 31, 2023
Mission and Program Overview
Mission
To fund research and public awareness focused on developing a cure for eosinophilic disorder
Document Assets
No mirrored PDF or thumbnail assets are attached yet.
Filings
Displayed year
2023 • Form 990Summary only. Only limited summary data is available for this year.
- Assets
- $280,783
- Liabilities
- $1,436
- Net assets
- $279,347
- Revenue
- $540,978
- Expenses
- $508,204
- Net income
- $32,774